Bartlett & CO. Wealth Management LLC Decreases Stock Holdings in Abbott Laboratories $ABT

Key Points

• Bartlett & CO. Wealth Management trimmed its stake in Abbott (NYSE:ABT) by 1.5% in Q4, selling 15,032 shares and now holds about 1,011,054 shares valued at roughly $126.7 million, making ABT its 14th largest position (~1.7% of the firm’s portfolio).
• Recent negative developments have pressured the stock — a Chicago jury ordered Abbott to pay about $53 million in a preterm infant formula trial, short interest rose ~19.4% in March, and analysts like Evercore have trimmed price targets, increasing near‑term downside risk.
• Despite the weakness (shares near $100 and down ~2.5%), Abbott pays a quarterly dividend of $0.63 (2.5% yield), reiterated 2026 guidance, and holds an average analyst rating of "Moderate Buy" with an average price target around $134.58, implying potential upside.

Bartlett & CO. Wealth Management LLC cut its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,011,054 shares of the healthcare product maker's stock after selling 15,032 shares during the period. Abbott Laboratories comprises about 1.7% of Bartlett & CO. Wealth Management LLC's investment portfolio, making the stock its 14th largest position. Bartlett & CO. Wealth Management LLC owned 0.06% of Abbott Laboratories worth $126,675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories in the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories in the 2nd quarter valued at $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth $33,000. 75.18% of the stock is currently owned by institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TD Cowen reiterated a Buy on ABT and kept a $137 price target, citing a resilient MedTech and diagnostics mix that supports Abbott's path to 2026 targets. TipRanks: TD Cowen Note
• Positive Sentiment: Citi recently initiated/maintained a Buy on ABT (coverage note reported), providing analyst support that can limit downside from headline risk. Globe & Mail: Citi Buy
• Positive Sentiment: Recent coverage highlighting Abbott as a dividend-king value/attractive yield may draw income-focused buyers who view current weakness as a buying opportunity. MarketBeat: Dividend King
• Neutral Sentiment: Abbott published consumer survey PR on chronic disease prevention (brand/marketing relevance). Useful for positioning but unlikely to move the stock materially in the short term. PR Newswire: Survey
• Neutral Sentiment: Wall Street previews note mixed expectations ahead of upcoming earnings (EPS growth expected but edge cases for a beat are limited), so the report could produce volatility but not a clear directional catalyst yet. Yahoo: Earnings Preview
• Negative Sentiment: A Chicago jury ordered Abbott to pay $53 million in compensatory damages in a preterm infant formula trial — a headline legal loss that raises litigation risk and investor concern about reputational and settlement exposure. Reuters: Jury Verdict
• Negative Sentiment: Short interest rose sharply in March (up ~19.4% vs. mid‑March), bringing total shorted shares to ~23.8M and a ~1.6 days-to-cover — increased bearish positioning can amplify downward moves on negative headlines.
• Negative Sentiment: Evercore trimmed its price target (reported) and broader healthcare stocks were weaker today, adding sector pressure; analyst and macro pressure can compound headline-driven selling. American Banking News: Evercore PT Cut

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company's stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company's stock, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Down 2.5%

Shares of NYSE:ABT opened at $100.17 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $99.34 and a 12-month high of $139.06. The stock has a market capitalization of $174.46 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 1.64 and a beta of 0.79. The stock has a fifty day simple moving average of $108.92 and a two-hundred day simple moving average of $119.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories's revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories's payout ratio is presently 67.74%.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. Evercore reduced their price objective on shares of Abbott Laboratories from $138.00 to $134.00 and set an "outperform" rating on the stock in a report on Monday, April 6th. Weiss Ratings cut Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, January 26th. BTIG Research lowered their target price on Abbott Laboratories from $140.00 to $131.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. Citigroup lowered their target price on Abbott Laboratories from $140.00 to $136.00 and set a "buy" rating on the stock in a report on Wednesday, March 11th. Finally, Argus decreased their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $134.58.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.